BioPharma Dive September 6, 2024
OrsoBio will use the funding to advance several weight loss medicines, while Vor shares rose on early trial data that appeared positive.
Today, a brief rundown of news from OrsoBio, as well as updates from Boehringer Ingelheim, Novartis and Vaxcyte that you may have missed.
OrsoBio, an obesity-focused startup backed by Eli Lilly, has raised $67 million in a Series B funding round, the company announced Friday. The cash will help advance a portfolio of weight loss medicines aimed at different drug targets than the GLP-1 therapies sold by Lilly and Novo Nordisk. Two of OrsoBio’s drugs are in Phase 2 testing for diabetes and metabolic dysfunction-associated steatohepatitis, while a third, oral medication should begin mid-stage testing “in the coming...
Today's Sponsors
Today's Sponsor